Mati Therapeutics
Austin, US · Founded 2012 · Delaware corporation
Mati Therapeutics develops a non-invasive sustained drug delivery platform, the Evolute Punctal Plug Delivery System, for treating ocular diseases such as glaucoma. The device delivers medication over an extended period, removing the need for patients to administer eye drops.
Founders & leadership
CN
Cameron NelsonExecutive
CM
Christopher MullerExecutive
DU
Deepank UtkedeExecutive
RB
Robert ButchofskyNamed on SEC filing
RL
Robert Lee Butchofsky IINamed on SEC filing
Board
JT
Joseph Tortorice IIIBoard director
DU
Deepank UtkhedeBoard director
Reported raises · per SEC filings
Form D private placements$12.9M disclosed across 5 rounds · 2014–2025
▶$2.6MraisedJul 2026 · 2 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJul 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ButchofskyExecutive Officer, Director
- Christopher MullerExecutive Officer, Director
- Joseph Tortorice IIIDirector
- Cameron NelsonExecutive Officer
- Peter McDonnellDirector
- Ken JonesDirector
- Jim MazzoDirector
- Dave FellowsDirector
- Linda LupiniDirector
- Offering amount
- $4.9M
- Amount sold
- $2.6M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.9MraisedOct 2025 · 13 investors · BiotechnologyRule 506(b)
▶$9.9MraisedOct 2025 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Deepank UtkhedeDirector
- Robert ButchofskyExecutive Officer, Director
- Christopher MullerExecutive Officer, Director
- Cameron NelsonExecutive Officer
- Joseph Tortorice IIIDirector
- Offering amount
- $10.5M
- Amount sold
- $9.9M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$165KraisedMay 2019 · 2 investors · BiotechnologyRule 506(b)
▶$165KraisedMay 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert Lee Butchofsky IIExecutive Officer, Director
- Cameron NelsonExecutive Officer
- Christopher MullerExecutive Officer, Director
- Deepank UtkhedeExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $165K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedOct 2018 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedOct 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert Lee Butchofsky IIExecutive Officer, Director
- Cameron NelsonExecutive Officer
- Christopher MullerExecutive Officer, Director
- Deepank UtkhedeExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $50K
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedOct 2014 · 2 investors · BiotechnologyRule 506(c)
▶$150KraisedOct 2014 · 2 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Deepank UtkedeExecutive Officer, Director
- Robert Lee Butchofsky IIExecutive Officer, Director
- Chris MullerExecutive Officer, Director
- Cameron NelsonExecutive Officer
- Offering amount
- $13.8M
- Amount sold
- $150K
- Sales commissions
- $690K
- Proceeds to insiders
- $1.3M
- Placement agents
- Carrollton Capital Partners, LLC
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMDI Therapeutics3 shared keywordsMDI Therapeutics is a pharmaceutical company developing small molecule therapies for fibrosis and fibroproliferative diseases, including MDI-2517, an inhibitor of plasminogen activator inhibitor 1 (PAI-1) currently in a Phase 1 clinical study. It operates in the biotech and drug development space.
Mirador Therapeutics3 shared keywordsMirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach. The company targets therapeutics to improve treatment efficacy beyond current standards in immunology and fibrotic conditions.
SoundCloud3 shared keywordsAudio distribution and music-sharing platform for artists and creators.
Companies competing with Mati Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Mati Therapeutics do?
- Mati Therapeutics develops a non-invasive sustained drug delivery platform, the Evolute Punctal Plug Delivery System, for treating ocular diseases such as glaucoma. The device delivers medication over an extended period, removing the need for patients to administer eye drops.
- How much funding has Mati Therapeutics raised?
- Mati Therapeutics has disclosed $12.9M raised across 5 rounds.
- Where is Mati Therapeutics headquartered?
- Mati Therapeutics is headquartered in Austin, US.